FindTrial
Sign In

Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC).

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-509095-42-00
Acronym
GEMCAD 2102
Enrollment
40
Registered
2024-07-03
Start date
2022-07-14
Completion date
2025-11-10
Last updated
2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Brief summary

Objective response rate.

Detailed description

Disease Control Rate., PFS., OS., Duration of response.

Interventions

DRUGOlaparib
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Sponsors

Grupo Espanol Multidisciplinar En Cancer Digestivo
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Objective response rate.—

Secondary

MeasureTime frame
Disease Control Rate., PFS., OS., Duration of response.—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026